Kobayashi Pharmaceutical Co. officially announced its withdrawal from the "red kojic" business in response to health claims made about its red kojic dietary supplement.

On March 22, Kobayashi Pharmaceutical announced that it had found that some red kojic ingredients in its red kojic-related products may contain unexpected ingredients, so it asked consumers to suspend use and implemented a voluntary recall of red kojic-related products.

Under such circumstances, the company announced at a board meeting held on August 8 that it had decided to withdraw from the red kojic business, taking into account the serious health damage it caused.

Even after exiting the business, the company will continue to compensate customers and business partners who have suffered health damage, investigate the causes and take other measures.

In addition, the company has decided to make it its corporate mission to identify all problems in the red kojic rice-related product production line and take measures to prevent them from happening again, and will continue to implement these measures.

Kobayashi began accepting compensation from complainants whose health was damaged due to the "red kojic" problem on August 19, and at the same time announced the manufacturing numbers of the relevant products.

Kobayashi Pharmaceutical Co. has announced that it will accept claims from August 19 from customers whose health was damaged by consuming its red kojic dietary supplements.

According to Kobayashi Pharmaceutical, the company will begin compensating people who have suffered health damage from taking red kojic dietary supplements containing "puberuic acid", including three products with specific manufacturing numbers that have been confirmed to contain or may contain "puberuic acid".

The relevant products are Red Kojic Cholesterol HELP, Lipid HELP + Cholesterol and Nattokinase SARASARA GOLD, which are aimed at people who, based on a comprehensive consideration of the contents of the doctor's diagnosis report, find that the intake of the above products is causally related to kidney-related diseases or other diseases.

The compensation includes four items: "medical expenses and transportation expenses" related to hospital visits, "compensation" for mental distress, "absence compensation" to compensate for the loss of income due to forced absence from work due to symptoms, and "loss of income caused by the aftermath of the injury" to compensate for the loss of future income due to symptoms.

Source: MBS NEWS

Note: This article is compiled by Antion. Please indicate the source for reprint.